神经退行性粉样蛋白疾病中的微生物粉样蛋白
1Department of Cell Biology, Emory University School of Medicine, Atlanta, GA, USA.
The FEBS journal
|December 2, 2023
概括
微生物粉样蛋白,微生物产生的蛋白质,越来越多地与神经退行性疾病有关. 准这些微生物粉样蛋白可能为治疗人类粉样蛋白病理提供了一个新的策略.
科学领域:
- 微生物学 微生物学
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 粉样纤维状结构并不仅限于人类疾病.
- 微生物产生功能性粉胺基蛋白质,这是它们生理学必不可少的.
研究的目的:
- 审查将微生物粉样蛋白与神经退行性疾病联系在一起的证据.
- 探索微生物粉样蛋白对宿主粉样蛋白病理学的影响.
主要方法:
- 对实验数据和新兴研究的文献综述.
- 微生物与宿主粉样蛋白之间的直接和间接相互作用的分析.
主要成果:
- 越来越多的证据表明,微生物粉样蛋白与神经退行性疾病有关.
- 微生物和宿主粉样蛋白之间的相互作用可能会导致粉样蛋白病理.
结论:
- 微生物粉样蛋白是宿主粉样蛋白疾病发展的潜在因素.
- 抑制微生物粉样蛋白或其宿主相互作用可能是粉样蛋白病理的治疗点.
更多相关视频
相关概念视频
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557


